Trefoil’s mission is to improve human health and create new therapies using drugs developed with protein engineering. Trefoil hopes to bring this novel therapy into clinical testing within 18 months. Other potential applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease.